Lupin launches generic female contraceptive in US
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Lupin Ltd. launched a generic version of Janssen Pharmaceuticals Inc.'s female contraceptive tablet Ortho-Cyclen.
The norgestimate and ethinyl estradiol tablets are approved by the U.S. FDA. Ortho-Cyclen generated $204 million in U.S. sales during the 12 months ended September 2016, according to IMS Health data.
Janssen Pharmaceuticals is a Johnson & Johnson unit.
